28216-32-2

Basic information

• Product Name: 1,1-di-p-anisylmethylisothiocyanate
• Synonyms: 1,1-di-p-anisylmethylisothiocyanate
• CAS NO: 28216-32-2
• Molecular Weight: 285.367
• Mol File: 28216-32-2.mol

Chemical Properties

• CAS DataBase Reference: 1,1-di-p-anisylmethylisothiocyanate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-di-p-anisylmethylisothiocyanate(28216-32-2)
• EPA Substance Registry System: 1,1-di-p-anisylmethylisothiocyanate(28216-32-2)

Safety Data

• Hazardous Substances Data: 28216-32-2(Hazardous Substances Data)

Upstream product

• 19293-62-0 p,p'-dimethoxybenzhydrylamine 
• 96989-50-3 di-2-pyridyl thionocarbonate 
• 75-15-0 carbon disulfide 

Downstream Products

• 144267-26-5 4,4-di-p-anisylthiazolidine-2,5-dithione 
• 1370633-24-1 (S)-1-(bis(4-methoxyphenyl)methyl)-3-(1-(diphenylphosphino)-3-phenylpropan-2-yl)thiourea 
• 144267-36-7 4,4-di-p-anisyl-1-palmitoyloxy-imidazolidine-2,5-dithione 
• 144267-49-2 4,4-di-p-anisyl-5-n-pentadecylthio-2,3-(4H)-dihydroimidazole-2-thione 
• 144267-31-2 1-hydroxy-4,4-di-p-anisylimidazolidine-2,5-dithione 

Relevant articles and documents

NOVEL SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS

The invention is directed to substituted benzimidazol-2-ones of Formula I, wherein A, X, Y, m, n, R1, R2, R 3, R4, and R5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating

The invention of radical reactions. Part XXVI. New thio- and seleno-hydroxamic acids; radical chemistry of their O-acyl derivatives

New thio- and seleno-hydroxamic acids have been synthesized from various 4,4-disubstituted thiazolidine 2,5-dithiones. Their corresponding O-acyl derivatives rearrange photochemically, with visible light, in an identical manner to the acyl derivatives of

Benzhydryl guanidines

Benzhydryl derivatives of guanidine (Formula I) having blood sugar lowering activity; pharmaceutical hypoglycemic compositions thereof and methods of administering same to hyperglycemic individuals.